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An increasing number of licensed human vaccines 
against infectious agents are based on recombinant 
proteins, including the hepatitis B virus (HBV) 
and  the  recently  developed  human  papilloma   
virus (HPV) vaccines (McAleer et al., 1984; 
Harper et al., 2004; Joura et al., 2007). These suc-
cessful vaccines demonstrate the principle that an 
effective antibody response can provide protec-
tion against real world challenges, providing en-
couragement for ongoing attempts to develop a 
vaccine against human immunodeficiency virus 
type 1 (HIV-1). However, unlike the HBV and 
HPV vaccines, which are produced as virus-like 
particles, most recombinant envelope glycopro-
teins (Envs) tested in immunogenicity studies so 
far are soluble and heavily glycosylated proteins, 
two properties which may have an impact on the 
elicited humoral response. Early attempts to stim-
ulate immune responses against HIV-1 using mo-
nomeric  Env  protein  administered  with  Alum 
failed  to  demonstrate  protection  (VAX04).  In 
contrast, recent results from the Thai phase III 
clinical trial (RV144) suggest that immunization 
regimens that include Env protein as a boost, after 
priming with a recombinant viral vector, decreases 
the risk of HIV-1 acquisition (Rerks-Ngarm   
et al., 2009). However, the protective effect ap-
peared to be transient and the mechanisms medi-
ating this, including potential antibody-mediated 
effects, are not yet determined.
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Broadly neutralizing antibodies (bNAbs) against the HIV-1 envelope glycoproteins (Envs) 
have proven difficult to elicit by immunization. Therefore, to identify effective Env neutral-
ization targets, efforts are underway to define the specificities of bNAbs in chronically 
infected individuals. For a prophylactic vaccine, it is equally important to define the immu-
nogenic properties of the heavily glycosylated Env in healthy primates devoid of confounding 
HIV-induced pathogenic factors. We used rhesus macaques to investigate the magnitude and 
kinetics of B cell responses stimulated by Env trimers in adjuvant. Robust Env-specific 
memory B cell responses and high titers of circulating antibodies developed after trimer 
inoculation. Subsequent immunizations resulted in significant expansion of Env-specific  
IgG-producing plasma cell populations and circulating Abs that displayed increasing avidity 
and neutralization capacity. The neutralizing activity elicited with the regimen used was, in 
most aspects, superior to that elicited by a regimen based on monomeric Env immunization 
in humans. Despite the potency and breadth of the trimer-elicited response, protection 
against heterologous rectal simian-HIV (SHIV) challenge was modest, illustrating the  
challenge of eliciting sufficient titers of cross-reactive protective NAbs in mucosal sites. 
These data provide important information for the design and evaluation of vaccines aimed  
at stimulating protective HIV-1 immune responses in humans.
© 2010 Sundling et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.rupress.org/terms). After six months 
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In this paper, we used rhesus macaques to assess the B cell 
response in a detailed and comprehensive manner after inoc-
ulation with soluble Env protein in adjuvant over a relatively 
long period of antigen exposure. Initially, we evaluated a 
panel of stimulation conditions to allow efficient in vitro ex-
pansion and differentiation of macaque memory B cells into 
antibody-secreting cells (ASCs). This allowed us to enumer-
ate the frequency of memory B cells and PCs from PBMC 
cultures and bone marrow after sequential immunization 
with soluble HIV-1 Env trimers. To our knowledge, this is 
the first time a comprehensive analysis of the stimulation 
conditions for HIV-1 Env-specific rhesus memory B cells is 
reported. Using these protocols, we demonstrate that each 
Env trimer boost resulted in a significant increase in periph-
eral Env-specific PCs, peaking at 20% of total IgG+ PCs 
before declining to baseline levels within 1 wk. This is similar 
to the response kinetics reported for other protein-based an-
tigens in humans (Wrammert et al., 2008; Blanchard-Rohner 
et al., 2009). Env-specific IgG+ memory B cells constituted 
between 10 and 20% of total IgG+ memory B cells in periph-
eral blood after two trimer inoculations and these levels re-
mained stable between the inoculations. These results suggest 
that, when administered at high doses and in a potent adju-
vant, the soluble HIV-1 Env immunogen used in this study 
does not appear to be a weak antigen in terms of the overall 
magnitude and kinetics of the elicited response. Furthermore, 
circulating Abs were generated that were capable of in vitro 
neutralizing a diverse panel of viruses. The response was con-
siderably broader than that measured in humans inoculated 
with monomeric Env in Alum in the VAX04 phase III clini-
cal trial, with the caveat that several variables need to be taken 
into account when making this comparison.
After our extensive immunogenicity analysis, we subjected 
the animals to rectal challenge with a heterologous SF162 Env-
based SHIV, SHIV-SF162P4. We observed a modest, but 
nonsterilizing, impact on acquisition of infection. The limita-
tion of the protective effect may be a result of the low levels of 
NAbs available in the rectal mucosa because the circulating 
Abs in plasma neutralized SHIV-SF162P4 with moderate po-
tency in vitro. The results presented in this paper highlight the 
challenge of achieving sterilizing protection against heterolo-
gous HIV-1 challenge. This study also provides benchmark 
immunogenicity results, which can be used to guide the design 
of Env-based immunization regimens that are under advance-
ment into human clinical trials.
RESULTS
Pokeweed mitogen (PWM) + Staphylococcus aureus Cowan 
(SAC) + CpG stimulation of PBMCs yields efficient 
differentiation of macaque memory B cells into PCs in vitro
Memory B cells do not produce Abs unless they are reacti-
vated by antigen or polyclonal stimulation to differentiate 
into ASC. Enumeration of total and antigen-specific memory 
B cells is greatly facilitated by methods to differentiate memory 
B cells into ASC to allow their detection by B cell ELISpot 
analysis. Several cytokines, mitogens, and toll-like receptor 
Despite the lack of protective correlates for HIV-1 infec-
tion, a vaccine that elicits broadly neutralizing antibodies 
(bNAbs) remains a high priority as this type of B cell response 
is likely to be most protective (Burton et al., 2004; Pantophlet 
and Burton, 2006; Karlsson Hedestam et al., 2008). Most an-
tiviral vaccines do protect via NAb, and several studies dem-
onstrate that passively administered NAbs can protect against 
challenge with simian-HIV (SHIV) in nonhuman primate 
(NHP) models (Baba et al., 2000; Mascola et al., 2000; Parren 
et al., 2001). A major limitation for current attempts to design 
an Env immunogen capable of eliciting bNAbs is the lack of   
a  high  resolution  structure  of  the  native  glycan-shrouded 
HIV-1 Env spike. Most recombinant trimers tested so far are 
empirical in their design and elicit Abs possessing relatively 
limited breadth of neutralization, perhaps as a result of their 
failure to faithfully mimic the functional Env spike (for review 
see Forsell et al., 2009).
During chronic HIV-1 infection, bNAbs develop, but only 
in a subset of individuals, and these responses do not usually ap-
pear until several years after establishment of chronic viral infec-
tion (for review see Stamatatos et al., 2009). Approximately 25% 
of infected individuals develop Ab responses capable of neutral-
izing a diverse set of primary viruses and a small percentage of 
this select group develops very broad and potent neutralizing re-
sponses (Doria-Rose et al., 2009; Sather et al., 2009; Simek et al., 
2009). Studies aimed at defining the Ab specificities present in 
individuals harboring broad plasma neutralization has intensified 
over the last few years as new methods to facilitate these analyses 
were described (Dhillon et al., 2007; Li et al., 2007; Binley et al., 
2008; Moore et al., 2008; Sather et al., 2009; Scheid et al., 
2009a,b). Recently, new broadly neutralizing mAbs were iso-
lated and characterized (Walker et al., 2009; Corti et al., 2010; 
Wu et al., 2010). These mAbs will provide valuable information 
for immunogen design, especially once their cognate target epi-
topes are defined at the atomic level of resolution.
In addition to the need to design more effective Env immu-
nogens, an improved basic understanding of vaccine-induced   
B cell responses in primates may be required to advance the de-
velopment of an effective prophylactic HIV-1 vaccine. To date, 
most HIV-1 Env-based vaccine studies examined the humoral 
immune responses at the serologic level, whereas only a few stud-
ies investigated anti-Env responses at the B cell level (Bonsignori 
et al., 2009; Dosenovic et al., 2009). An increased focus on the 
cells that produce vaccine-elicited antibodies is therefore needed 
to guide efforts to better replicate the successful generation of 
bNAbs that is seen in some infected humans. Examination of 
neutralizing mAbs isolated from chronically HIV-1–infected in-
dividuals suggests that extensive Ab affinity maturation is required 
to achieve efficient neutralization (Burton et al., 1994; Scheid   
et al., 2009b; Walker et al., 2009). However, little is known 
about how B cell selection in the germinal center reaction can be 
stimulated most effectively with nonreplicating subunit vaccines 
to drive somatic mutation of Ab genes. Additionally, we lack 
knowledge regarding how different immunization regimens   
affect the development of Env-specific memory B cell and plasma 
cell (PC) populations in healthy primate subjects.JEM VOL. 207, August 30, 2010 
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of ASC (total and Env-specific) was present in the culture   
after 4 d and declined thereafter (Fig. S2 A), whereas maxi-
mal accumulation of Abs in the supernatant required an 
additional 4 d of culture (Fig. S2 B). The frequencies of 
Env-specific ASC and secreted IgG in the supernatant were 
similar at all time points measured for both stimulation con-
ditions (Fig. S2, A and B).
The phenotype of the B cells cultured in the presence of 
PWM + SAC + CpG or IL-2 + IL-10 + CpG + CD40L was 
also investigated. As shown in Fig. 2 A, the largest fraction of 
IgG-expressing cells (20%) of the CD4/CD8-negative popu-
lation was found in the PWM + SAC + CpG–stimulated 
cultures. The corresponding population in the IL-2 + IL-10 + 
CpG + CD40L–stimulated culture was 7.8%. As expected, 
only cells displaying low CD20 expression were IgG produc-
ers and no CD20 down-regulation was observed in nonstim-
ulated control cultures (Fig. 2 A). To assess the proliferative 
capacity of lymphocytes in response to the different stimuli, 
PBMCs were CFSE stained and incubated with PWM + SAC + 
CpG, IL-2 + IL-10 + CpG + CD40L, or CpG alone. The 
proliferation of T cells (CD4+, CD8+, and CD20) and   
B cells (CD4, CD8, and CD20+/low) was evaluated after 6 d 
of culture. Consistent with the B cell ELISpot results, the 
PWM + SAC + CpG cocktail stimulated B cell expansion 
and differentiation most efficiently. This cocktail also stimu-
lated T cell proliferation (Fig. 2 B). In contrast, IL-2 + IL-10 + 
CpG + CD40L and, to a lesser extent CpG alone, stimu-
lated B cell proliferation and down-regulation of CD20   
but not T cell proliferation. To further elucidate the role of   
T cells for the responsiveness of human and rhesus PBMCs to 
ligands were described as important factors for the prolifera-
tion and differentiation of human memory B cells into ASC 
(Arpin et al., 1995; Krieg et al., 1995; Crotty et al., 2004; 
Amanna and Slifka, 2006; Huggins et al., 2007). To establish 
protocols for efficient macaque memory B cell differentiation, 
we used rhesus and cynomolgus macaque PBMCs collected 
14 d after Env immunization. At this time, circulating PCs 
are not detected by direct B cell ELISpot analysis, whereas 
memory B cells require a period of in vitro expansion and 
differentiation into ASC before they are detected (Fig. S1). 
The ELISpot assay used in this study is based upon a recently 
described protocol where total IgG is captured on the plate 
and antigen-specific IgG is detected with biotinylated Env 
probes, generating high definition spots with low background 
(Dosenovic et al., 2009).
We evaluated a panel of stimuli for in vitro differentiation 
of macaque memory B cells. The efficiency of the stimula-
tions varied considerably, with a combination consisting of 
PWM, SAC, and CpG (PWM + SAC + CpG) being the most 
potent under the conditions tested in this study (Fig. 1 B). 
There was a strong correlation between the number of Env-
specific and total IgG+ memory B cells per million cultured 
PBMCs,  indicating  nonbiased  polyclonal  stimulation   
(r2 = 0.9209; Fig. 1 B). A strong correlation between the 
number of Env-specific memory B cells detected by ELISpot 
assay and secreted Ab measured by ELISA was also observed 
(r2 = 0.9273; Fig. 1 C). To compare the quality of the re-
sponse stimulated by PWM + SAC + CpG or IL-2 + IL-10 + 
CpG + CD40L, we also measured the kinetics of the re-
sponse. For both stimulation conditions, the highest number 
Figure 1.  Differentiation of macaque memory B cells into ASC in vitro. (A) PBMCs isolated from rhesus macaques inoculated with Env trimers in adjuvant 
were stimulated 4 d in vitro for differentiation of memory B cells into ASC. Stimulations were performed in 48-well plates with combinations of CpG, IL-2, IL-10, 
CD40L, anti-CD40, SAC, and PWM as indicated. PWM (underlined) was tested at concentrations ranging from 10 µg/ml to 1 ng/ml. Stimulated cells were added to 
ELISpot plates for detection of total and Env-specific IgG-producing cells. Bar graphs represent mean values + SEM of two to three monkeys normalized to 106 
cultured PBMCs. (B) The correlation between Env-specific and total IgG-producing ASCs was determined for each stimulation after log10 transforming the values. 
(C) The correlation between Env-specific ASC quantified by B cell ELISpot assay and secreted Env-specific Abs quantified by ELISA for each stimulation condition 
was determined. Pearson’s correlation (r2) and the p-value for the correlation efficiency are shown. The experiment was repeated three times.2006 B cell responses against Env trimers in primates | Sundling et al.
stimulation by PWM, PWM + SAC, PWM + SAC + CpG, 
IL-2 + IL-10 + CpG + CD40L, or CpG alone, B cells were 
sorted and cultured in the presence or absence of autologous 
T cells and the different stimuli. The results demonstrate that 
the stimulatory effect of PWM on both human and rhesus 
memory B cells was dependent on the presence of T cells. 
Only the IL-2 + IL-10 + CpG + CD40L cocktail induced 
differentiation of human and rhesus memory B cells in the 
absence of T cells (Fig. 2 C). The data also show that   
human memory B cells were more responsive to CpG than 
rhesus memory B cells under the assay conditions used in 
this study (Fig. 2 C).
Boosting results in high HIV-1 Env-binding Ab titers  
and increased Ab avidity
To  examine  the  kinetics  by  which  antigen-specific  Abs, 
memory B cells, and PCs develop in response to Env immu-
nizations, rhesus macaques were inoculated with HIV-1 Env 
trimers in adjuvant (immunized) or adjuvant alone (controls) 
via the i.m. route. We used cleavage-defective soluble gp140 
trimers (gp140-F) derived from the primary clade B isolate 
YU2. The trimers possess a heterologous trimerization motif 
from fibritin (F), as previously described (Yang et al., 2002). 
The schedule for inoculations and sample collections is shown 
in Fig. 3 A. Plasma and PBMCs were collected before the first 
protein inoculation and 1 and 2 wk after each inoculation. 
Bone marrow samples were collected 3 wk after the second 
and fourth inoculations. 1 mo after the last inoculation, all an-
imals were challenged with SHIV-SF162P4 to assess the pro-
tective capacity of the immune response.
Plasma from Env trimer-inoculated animals were tested 
for binding Abs to YU2 Env by ELISA (gp120; Fig. 3 B). 
The data are shown as half-maximum binding titers of Env-
specific IgG and IgA (Log10 optical density [OD] 50 titers). 
Env-specific IgG responses were detected 2 wk after the first 
inoculation and they were boosted by the second inoculation, 
resulting in OD50 titers of 105, which were maintained   
after the subsequent inoculations. Env-specific IgA responses 
were 1.5 log lower but followed the same kinetics. The re-
sponse was comparable between individual animals for both 
IgG and IgA. When the plasmas were examined for increases 
in functional affinity, often referred to as avidity, using a more 
stringent binding assay involving incubation in 1.5 M NaSCN 
(see Materials and methods), we recorded an enhancement in 
avidity with repeated boosting (Fig. 3 C). These data demon-
strate that i.m. immunizations with Env trimers administered 
in Abisco-100 and CpG ODN 2395 elicit potent plasma Ab 
responses, which evolve with repeated antigen exposure. To 
investigate if this increase was selective for subspecificities of 
Env, we performed the avidity assay with three trimeric YU2-
based Env probes: gp140-F, gp120-F, and gp120V1/2/3-F 
(Dosenovic et al., 2009). We observed a significant increase in 
Figure 2.  Phenotypic characterization of rhesus macaque lympho-
cytes after in vitro stimulation. (A) Rhesus macaque PBMCs were stimu-
lated with PWM + SAC + CpG, IL-2 + IL-10 + CpG + CD40L, or were 
nonstimulated (n-s) for 4 d and then stained for CD20, CD4, CD8, and intra-
cellular IgG (IC-IgG). Nonviable cells were excluded via forward scatter and 
side scatter gating and B cells were defined as CD4CD8CD20+/low cells.  
The numbers in the quadrants represent the percent cells of the total 
CD4CD8CD20+/low cell population. The dot blots are representative of two 
donors. (B) Rhesus PBMCs were stained with CFSE and stimulated with  
PWM + SAC + CpG, IL-2 + IL-10 + CpG + CD40L, or CpG or nonstimulated 
for 6 d. Proliferation of CD20+/low CD4CD8 B cells (bottom) and 
CD20lowCD4+CD8+ T cells (middle) was analyzed. The numbers represent the 
percentage of cells in each indicated gate of total cells gated on side scatter/
forward scatter. The dot blots and histograms are representative of two do-
nors. (C) CD19+ or CD20+ B cells and CD4+ T cells were isolated from human 
(right) and rhesus macaque (left) PBMCs. The B cells were stimulated alone 
(white) or in combination with T cells (black) for 7 d and IgG production was 
evaluated by ELISA. The bar graph describing human data represents mean 
and standard deviation of triplicate samples. Stimulations on sorted human 
B cells were independently repeated three times with similar results. Data 
from rhesus macaque PBMCs represent mean and SEM of three donors.
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the avidity index between the samples after immunization   
two and after immunization five for all three probes (Fig. 3 D). 
Furthermore, there was no significant difference between   
the avidity indexes for the three probes at either time point 
(Fig. 3 E). These results indicate that the increase in avidity 
between the second and fifth immunization was not selective 
for variable region 1–3 determinants (which are absent from 
gp120V1/2/3-F) or for gp41 determinants (which are ab-
sent from gp120-F and gp120V1/2/3-F) but probably re-
flect overall avidity increases for several determinants displayed 
by these complex glycoprotein immunogens.
Boosting results in transient peaks of Env-specific PCs  
and high levels of memory B cells
To examine the dynamics of Env-specific memory B cells and 
PCs in the Env trimer-inoculated animals over the prime/boost 
regimen, we collected PBMCs 1 and 2 wk after each inocula-
tion. The cells were either plated directly in ELISpot plates for 
detection of PCs or stimulated in vitro for 4 d with PWM, 
SAC, and CpG for detection of memory B cell–derived ASC. 
Circulating PCs are presented as ASC per 106 PBMCs (Fig. 4 A, 
top) and as the percent Env-specific of total IgG-producing 
cells (Fig. 4 A, bottom). Circulating memory B cells are pre-
sented as ASC per 106 cultured PBMCs (Fig. 4 B, top) and as 
the percent Env-specific of total IgG-producing cells (Fig. 4 B, 
bottom). The results demonstrate that the frequencies of total 
IgG+ PCs and memory B cells were stable during the course of 
the immunization schedule in both control and Env trimer- 
inoculated animals. In contrast, Env-specific PCs peaked 1 wk 
after each Env inoculation and then declined to near baseline 
levels. Env-specific memory B cells were detectable 2 wk after 
the first inoculation and achieved peak levels 1 wk after the   
second inoculation. Thereafter, the frequency of Env-specific 
memory B cells was maintained at stable levels at the time points 
measured. Though not shown in these animals, a decline in 
specific memory B cells at later time points after protein inocu-
lation is expected based on data from another set of animals 
where we analyzed additional time points after immunization 
(Fig. S3). No Env-specific PC or memory B cells were detected 
in the adjuvant-only inoculated control animals.
We also examined the frequency of Env-specific PCs in 
the bone marrow after both the second and the fourth trimer 
inoculations. Approximately 3% of total IgG+ PCs were Env 
specific at both time points (Fig. 4 C). We did not detect any 
memory B cells in the bone marrow using either PWM + 
SAC + CpG stimulations or IL-2 + IL-10 + CpG + CD40L, 
which stimulates memory B cells in the absence of T cells 
(Fig. 4 D). These data suggest that memory B cells are rare in 
the bone marrow of rhesus macaques.
An important issue to address is if Env selectively boosts   
B cells that recognize specific regions of the trimers during the 
immunization regimen. To determine the subspecificities of 
circulating Abs and memory B cells, and to ask if these specifici-
ties shift during the course of the immunization schedule, we 
used the same series of trimeric Env probes as described in the 
previous section (gp140-F, gp120-F, and gp120V1/2/3-F). 
Figure 3.  Development of anti-Env binding Abs in Env trimer-
inoculated macaques. (A) Schematic representation of the study design. 
Inoculations (black arrows) were given monthly for 5 mo with Env trimers 
in Abisco-100 + CpG to six monkeys (F123-F128). Six other monkeys were 
inoculated with Abisco-100 + CpG alone. Blood (red arrowheads) was 
collected 1 and 2 wk after each inoculation. Bone marrow (blue arrow-
heads) was sampled 3 wk after the second and fourth protein inoculation. 
The animals were challenged (green arrow) with SHIV-SF162P4 virus 5 wk 
after the last vaccination. (B) Env-binding IgG and IgA Abs were measured 
2 wk after each inoculation (Pre, preimmunization; Imm 1, first immuni-
zation). Binding titers are presented as Log10 OD50 titer, and the black line 
corresponds to the mean of six monkeys. (C) Avidity index was measured 
2 wk after each inoculation with the individual monkeys (n = 6) shown. 
The experiment was repeated at two independent occasions with similar 
results for the IgG measurements and once for the IgA measurements.  
(D) Avidity index against gp140-F, gp120-F, and gp120V1/2/3-F in sam-
ples collected 2 wk after immunizations two and five (n = 6). The experi-
ment was performed once. (E) Comparison of avidity index against the 
different Env antigens in the same samples as in D. The experiment was 
performed once. The box plots illustrate the following: horizontal line, 
median; plus, mean; box, interquartile range; whiskers, min/max and error 
bars, +SEM. Significance was evaluated using ANOVA. ns, nonsignificant. 
*, P ≤ 0.05; **, for P ≤ 0.01; ***, for P ≤ 0.001.2008 B cell responses against Env trimers in primates | Sundling et al.
immunization. The results were different when the superna-
tants from PWM + SAC + CpG–stimulated PBMCs were ana-
lyzed in ELISA coated with the different Env probes. After 
converting the data to the percent region specific of total Env-
specific reactivity, there was nearly no detectable gp41-specific 
response. Also, there was no difference in the relative reactivity 
against variable region versus other during the course of the im-
munizations. A similar pattern was observed when the plasma 
was analyzed by differential ELISA (Fig. 4 E). These results sug-
gest that analyses based on ELISA, which measures secreted Ab 
in solution, are not sufficiently sensitive to measure subtle shifts 
We determined the frequency of memory B cells reactive to the 
three probes using subtractive analysis to calculate the percent-
age  of  gp41-reactive,  V1/2/3-reactive,  and  non-gp41/non-
V1/2/3 (termed “other”) fractions. By plotting the data as the 
percent region specific of total Env-specific memory B cells, 
the results reveal that a considerable fraction (30% of memory 
B cells) was directed against gp41 after two immunizations, but 
this fraction diminished during the course of the vaccination 
schedule to 10% of the total Env-specific response (Fig. 4 E). 
In contrast, the fraction directed against the gp120 variable   
regions expanded over time and especially after the third 
Figure 4.  Dynamics of total and Env-specific B cell subsets in peripheral blood and bone marrow. The frequencies of total and Env-specific PCs  
(directly plated) and memory B cells (4 d in vitro stimulation with PWM + SAC + CpG before plating) were determined by B cell ELISpot analysis in animals inocu-
lated with Env trimers in Abisco-100 + CpG (immunized) or Abisco-100 + CpG alone (controls). (A) The top shows total PC from immunized (black) and control 
(green) animals and Env-specific PCs from immunized (red) and controls (blue) in blood, plotted as ASC/106 PBMC. Circles indicate group mean ± SEM (n = 6). 
The bottom shows the percentage of Env-specific of total PCs, with individual animals (F123-F128) shown as different symbols. (B) The top shows frequencies 
of total and Env-specific IgG+ memory B cells as group means, plotted as ASC/106 cultured PBMC. The bottom shows the percentage of Env-specific of total 
IgG+ memory B cells for individual animals. (C) The top shows total and Env-specific PC in bone marrow samples (BM PC) collected 3 wk after inoculations two 
and four, plotted as ASC/106 BM cells. The bottom shows the percent Env-specific of total PC in bone marrow for individual animals. The error bars represent 
means ± SEM. (D) Bone marrow cells from individual animals were cultured in vitro with PWM + SAC + CpG or IL-2 + IL-10 + CpG + CD40L or were left non-
stimulated for 4 d. Data are shown as ASCs per 106 cultured bone marrow cells and significance was determined using ANOVA. The experiment was performed 
at two independent occasions with similar results. (E) Subspecificities of the B cell responses 2 wk after each inoculation were measured using a differential 
ELISpot assay (left) and differential ELISA (middle and right). Bars represent fractions of subspecificities of total gp140-specific responses, presented as the per-
centage of region-specific of total Env responses ± SEM (n = 6). Differential ELISA experiments were performed on three separate occasions with similar results 
and the differential B cell ELISpot was performed once for each time point. ns = nonsignificant. *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001.JEM VOL. 207, August 30, 2010 
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DJ263 and MW965 was obtained, suggesting some breadth 
of neutralization across HIV-1 clades. Furthermore, we 
also observed neutralization of viruses pseudotyped with the 
HIV-2 Env in the presence of subinhibitory concentrations 
of soluble CD4. This assay detects the presence of coreceptor 
binding site–directed Abs (Decker et al., 2005), which are 
elicited in NHPs inoculated with soluble HIV-1 Env immu-
nogens (Forsell et al., 2008; Douagi et al., 2010).
To benchmark the soluble YU2 trimers used in the im-
munization regimen in this study against the recombinant 
gp120 protein regimen used in the VAX04 trial, we obtained 
20 clinical serum samples from VAX04 collected 2 wk after 
four inoculations with MN and GNE8-derived gp120 protein 
in Alum. The samples were analyzed for neutralizing activity 
using the same panel of viruses and the same assay conditions 
as used for the NHP samples described in the previous para-
graph. To strengthen the comparison, we included data from 
10 animals described in our previous studies: five rhesus ma-
caques inoculated with YU2 trimers in Abisco-100 + CpG 
(Douagi et al., 2010) and five cynomolgus macaques inocu-
lated  with  YU2  trimers  in  GSK  Adjuvant  system  AS01B 
(Mörner et al., 2009). The results demonstrate that the neu-
tralizing activity elicited by the monomers (VAX04) and the 
trimers (NHP) was comparable against MN, whereas the tri-
mers elicited superior neutralizing activity against all other   
viruses tested except ADA (Fig. 6). With the caveat that 
somewhat higher anti-Env binding Ab titers were achieved in 
the NHP study than in the VAX04 study (unpublished data), 
perhaps as a result of the use of different adjuvants, these data 
demonstrate that improved NAb responses can be generated 
by optimized subunit Env protein immunization regimens.
SHIV challenge and analysis of Ab binding titers  
in mucosal washes
Although the major and primary goal of this study was to de-
fine the kinetics and magnitude of the B cell response elicited 
in Ab subspecificities, likely as a result of competition between 
Abs of different specificities in this assay format.
The YU2 trimers elicit NAbs capable of neutralizing clade A, 
B, and C viruses, and the response is broader than that 
elicited in the VAX04 study
To investigate the NAb activity elicited by the Env trimers, 
we examined the capacity of the plasma collected after two 
and five immunizations to neutralize a panel of HIV-1 iso-
lates. The selected isolates are known to display varying de-
grees of neutralization sensitivity (Li et al., 2005). The panel 
included clade B isolates representing neutralization-sensitive 
viruses (tier 1) and isolates representing more neutralization-
resistant primary circulating variants (tier 2). Recombinant 
viruses were pseudotyped with the following clade B Envs: 
MN, HxBc2, SF162, and BaL.01; and the following tier   
2 clade B Envs: YU2, 89.6, 6535, and ADA. In addition, vi-
ruses were pseudotyped with one clade A (DJ263) and one 
clade C (MW965) Envs. The data are presented as 50% 
plasma inhibitory dilution (ID50) values. In agreement with 
previous studies in rhesus macaques (Mörner et al., 2009; 
Douagi et al., 2010), we observed potent ID50 neutralizing 
titers against several Tier 1 viruses and detectable, but less 
potent, neutralization against some Tier 2 viruses (Fig. 5 A). 
Mean ID50 neutralization titers against MN were 1,000   
after two immunization and these responses were significantly   
increased after five immunizations. High ID50 titers against 
HxBc2 and SF162 were also measured after two immuniza-
tion and these responses were boosted by the subsequent im-
munizations. Neutralization of viruses pseudotyped with the 
neutralization-resistant homologous YU2 Env was observed 
in three animals after two immunizations and in five animals 
after five immunizations. A similar pattern was observed for 
ADA. There was no or only sporadic neutralization of 89.6, 
6535, TRO.11, JRCSF, or REJO (Fig. 5 A and not de-
picted). In contrast, neutralizing activity against Tier 1 viruses 
Figure 5.  Maturation of neutralizing Ab responses 
with repeated immunizations. Neutralizing activity in 
plasma collected 2 wk after the second and fifth inoculations 
of Env-immunized macaques (red; n = 6) and controls (blue; 
n = 6) using the TZM-bl pseudovirus assay. The analysis was 
performed once, at multiple dilutions of each plasma sample. 
Data from individual animals are shown as the reciprocal 
dilution giving 50% neutralization (ID50) with group means ± 
SEM indicated. Clade B HIV-1 isolates that are sensitive (tier 1) 
or resistant (tier 2) to neutralization were examined. The 
viruses tested were: tier 1 clade B viruses MN, HxBc2, SF162, 
and BaL.01 (top left); and Tier 2 clade B viruses YU2, 89.6, 
6535, and ADA (top right). The clade A virus DJ263 (bottom 
left) and the clade C virus MW965 (bottom middle) were also 
examined. Plasma was also tested for the presence of core-
ceptor binding site-directed Abs (CoRbs Abs) that neutralize 
virus pseudotyped with HIV-2 Env in the presence of subin-
hibitory concentration of soluble CD4 (sCD4; bottom right). 
ID50 values between inoculations two and five were com-
pared with repeated measures ANOVA. ***, P < 0.001.2010 B cell responses against Env trimers in primates | Sundling et al.
but no animal in the vaccine group. After the second chal-
lenge, four control animals were infected compared with two 
in the Env-immunized group. The remaining animals in the 
control group were infected after the third exposure, whereas 
six exposures were required to infect all animals in the Env-
immunized group. This result suggests that there is a trend to-
ward a modest degree of protection in the vaccine group; 
however, it is not statistically significant. Further studies in-
volving larger groups of animals are needed to confirm this 
trend. We also asked if the high plasma Ab titers measured in 
the immunized animals (Fig. 3 B) provided a benefit in terms 
of control of viremia once the animals were infected. We mea-
sured this by cumulative viral loads during the viremic period 
(area under the curve calculated from viral load curves shown 
in Fig. S6; Fig. 7 A, middle) and by peak viral load (Fig. 7 A, 
right panel). By both measures, there was a trend for the im-
munized animals to better control the infection, but the differ-
ence between the groups was not statistically significant.
The modest, but suggestive, effect observed in the chal-
lenge experiment led us to analyze additional parameters of the 
prechallenge immune response. We first asked if the prechal-
lenge plasma contained Abs capable of neutralizing either the 
SHIV-SF162P4 stock or recombinant virus pseudotyped with 
an Env clone derived from the SHIV-SF162P4 stock, clone 
41.1. Moderate ID50 neutralization titers ranging between 200 
and 300 were measured against both the stock and the cloned 
virus (Fig. 7 B). Some background activity against the stock 
was observed in the plasma from the control immunized ani-
mals, but not against the pseudotyped cloned virus, suggesting 
that the latter assay is less prone to nonspecific serum effects.
To further address why more efficient protection against 
SHIV-SF162P4 challenge was not achieved despite detectable 
plasma neutralizing activity against the challenge virus in the 
immunized animals, we measured Env-specific and total IgG 
and IgA titers in mucosal lavages collected 2 wk after each im-
munization (Fig. 7 C, top). Env-specific IgG was detected in 
both  rectal  lavages  and  vaginal  lavages  and  these  responses   
correlated weakly (rectal lavages) or strongly (vaginal lavages) 
with the plasma Ab titers measured in the corresponding ani-
mal (Fig. 7 C, bottom). Env-specific IgA in vaginal lavages and 
rectal lavages were below detection (unpublished data). By com-
paring all data points from the vaginal and rectal samples col-
lected between the second and the fifth immunization with the 
corresponding  IgG  concentrations  measured  in  plasma,  we 
conclude that the IgG concentrations in vaginal lavages are 
1,000-fold lower than in plasma and the IgG concentrations 
in the rectal lavages are 10,000-fold lower than in plasma 
(Fig. 7 D). These lower levels of antibody just outside the mu-
cosa, presumably as a result of inefficient exudation, may not 
be sufficient to neutralize all incoming virus before interaction 
with CD4+/CCR5+ target cells in this challenge model.
DISCUSSION
Vaccine-induced neutralizing antibody and memory B cell recall 
responses play critical roles in preventing infection and limit-
ing virus dissemination. Although there is a pressing need to   
by the soluble HIV-1 Env trimers in healthy primates, the 
potent response observed in this study led us to ask if this could 
mediate  protection  against  heterologous  SHIV  challenge.   
We used the SHIV-SF162P4 challenge virus, which induces 
high  but  transient  viremia  in  rhesus  macaques  (Harouse   
et al., 1999; Barnett et al., 2008; Polacino et al., 2008). To 
model one route of human mucosal transmission via sexual 
exposure, we subjected the animals to repeated rectal expo-
sures, two per week, using a moderate dose of virus (50 
TCID50). This dose corresponds to 3 × 106 virus RNA 
copies, which is within the physiological range of one trans-
mission event (Chakraborty et al., 2001; Pilcher et al., 2004). 
From previous in vivo titration results, we predicted that this 
dose would infect the Env-naive control animals in a few ex-
posures, thus representing a higher dose than that estimated 
in humans under average transmission conditions but a lower 
dose than in some other SHIV studies (Barnett et al., 2008, 
2010; Bogers et al., 2008). Blood was collected at each chal-
lenge occasion for detection of plasma viremia.
The Kaplan-Meier graph in Fig. 7 A (left) shows the per-
centage of uninfected animals after each challenge. After one 
challenge, one macaque in the control group became infected 
Figure 6.  Comparison of neutralizing activity in trimer-immunized 
macaques and monomer-immunized humans. The ID50 NAb titers in 
Env trimer-immunized macaques (NHPs; n = 16) and gp120 monomer-
immunized humans participating in the VAX04 study (n = 20) were com-
pared. The analysis was performed once, at multiple dilutions of each 
plasma sample. Plasmas were assayed against clade B Tier 1 viruses MN, 
HxBc2, SF162, and BaL.01 (top) and Tier 2 viruses YU2, 89.6, 6535, and 
ADA (middle), and against the clade A virus DJ263 (bottom left) and the 
clade C virus MW965 (bottom right). Significance was determined using 
ANOVA. ns = nonsignificant. ***, P ≤ 0.001.JEM VOL. 207, August 30, 2010 
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The rapidity of the recall response suggests that it originates 
from circulating memory B cells that differentiate into PCs in 
the periphery or that it arises from circulating memory B cells 
that enter already existing germinal center reactions, as shown 
in a recent study (Schwickert et al., 2009). We also demon-
strate that Env-specific IgG+ memory B cells peaked 2 wk   
after the second immunization and remained at stable levels 
between immunizations, comprising 10–20% of total IgG+ 
memory B cells. This pool is likely maintained by the frequent 
boosting regimen and would be expected to wane with time 
in the absence of antigen. We did not investigate the sustain-
ability of the Env-specific memory B cell and PC pool over 
time once inoculation of antigen was terminated, but this is an 
important issue to address in future studies. Previous studies 
showed that the Ab response to gp120 immunization was 
poorly sustained after clearance of antigen (Anderson et al., 1989; 
Graham et al., 1996), suggesting a lack of long-lived PCs. 
understand relevant B cell responses an effective HIV-1 vaccine 
should elicit, a detailed analysis of the magnitude and kinetics of 
Env-specific memory B cells and PCs generated in response to 
Env protein immunizations in humans or NHPs is currently 
lacking. Accordingly, we analyzed the generation of Env-specific 
B cell populations in rhesus macaques inoculated with recombi-
nant Env trimers in adjuvant. We assessed the functionality of 
the response at several levels, including requirements for activa-
tion of resting macaque memory B cells, elicitation of Env- 
specific binding Abs and increases in avidity after prolonged 
antigen exposure, neutralization capacity of Env-elicited anti-
bodies in vitro, and protection against in vivo SHIV challenge.
We  demonstrate  that  Env-specific  IgG-producing  cells 
peaked 7 d after each boost and then declined sharply. This is 
similar to the kinetics reported for other vaccine antigens 
where boosting results in a transient burst of PCs (Blink et al., 
2005; Wrammert et al., 2008; Blanchard-Rohner et al., 2009). 
Figure 7.  SHIV-SF162P4 rectal challenge and mucosal Env-specific Ab responses. Macaques immunized with YU2 trimers in adjuvant (F123-F128, 
red symbols; n = 6) or adjuvant alone (F129-F134, blue symbols; n = 6) were challenged with 50 TCID50 SHIV-SF162P4 twice a week via the rectal route 
until confirmed infected by Q-RT-PCR. (A) The Kaplan-Meier graph illustrates percentage of uninfected animals after each challenge occasion (left). Differ-
ence in number of challenges needed to achieve infection was determined by Log-rank (Mantel-Cox) test where P < 0.05 was considered significant. The 
cumulative viral load (middle) is shown as log10 area under curve where each symbol represents an individual animal. Immunized and controls were com-
pared with the Mann-Whitney test. Peak viral load (right panel) was measured at time of peak viremia for each individual animal and groups were com-
pared with the Mann-Whitney test. Box plots show interquartile range and whiskers min-max values. (B) Plasma collected 2 wk after inoculation five from 
immunized (red, n = 6) and control (blue, n = 6) animals were assayed for neutralization against the SHIV-SF162P4 clone (41.1) and stock. Evaluation of 
neutralization was done with ANOVA. (C) Env-specific and total IgG in rectal lavages (RL, left) and vaginal lavages (VL, right) were measured 2 wk after each 
immunization. Circles represent group means (n = 3–6) ± SEM. Correlates between plasma and mucosal Env-specific IgG (of total IgG) for rectal samples 
(bottom left) or vaginal samples (bottom right) with linear regression shown. Correlations (r2) were determined through Pearson’s correlation analysis where 
P < 0.05 was considered significant. (D) Total levels of IgG (black, n = 21–24) and Env-specific IgG (red, n = 21–24) was quantified in plasma, rectal, and 
vaginal washes. Concentrations from all data points after reaching peak levels (immunization two to five) are shown. For comparison between compart-
ments data were evaluated for significance via ANOVA. Lines and error bars indicate group mean ± SEM. ns, nonsignificant. ***, for P ≤ 0.001.2012 B cell responses against Env trimers in primates | Sundling et al.
The recent results from RV144 indicate that boosting 
with purified Env protein in adjuvant after priming with a 
recombinant canary pox vector provided a modest but tran-
sient protective effect in low risk populations (Rerks-Ngarm 
et al., 2009). Several preclinical studies also demonstrate that 
boosting with recombinant Env protein elicits high Ab re-
sponses after priming with recombinant viral vectors or DNA 
(Montefiori et al., 1992; Lubeck et al., 1997; Forsell et al., 
2005; Shu et al., 2007; Mörner et al., 2009). Both VAX04 
and RV144 used gp120 administered in Alum, an adjuvant 
known to stimulate Th2-biased immune responses (Marrack 
et al., 2009). However, because RV144 used a viral vector to 
prime the response, this might lead to a different spectrum of 
Ab isotypes than those elicited in VAX04, which used pro-
tein in Alum adjuvant alone. A difference in Ab isotypes 
could affect Ab-mediated activities such as ADCC. Consis-
tent with shifts in Ab isotypes, we demonstrated previously 
that priming with an Env-expressing recombinant Semliki 
Forest virus vector resulted in an Ab response that remained 
Th1 biased even after boosting with Env protein in a Th2-
biasing adjuvant (Forsell et al., 2005). In the current study, we 
used an adjuvant consisting of Abisco-100 and CpG, which stim-
ulates Th1-biased responses  including  generation  of IFN-– 
producing CD4+ and CD8+ T cells (Douagi et al., 2010).   
A better understanding of the role for Ab isotypes relative to 
antibody neutralization and protection against infection is an 
important issue yet to be clarified (Liu et al., 2003; Huber 
and Trkola, 2007; Nimmerjahn and Ravetch, 2008).
Previous studies established that protection against SHIV 
challenge via the mucosal route was achievable by either ac-
tive immunization with a homologous Env-based immuno-
gen (Barnett et al., 2008, 2010; Bogers et al., 2008) or by 
passive infusion of Env-directed neutralizing Abs (Mascola   
et al., 2000; Hessell et al., 2009a,b). However, heterologous 
challenge to Env vaccine-elicited B cell responses is rarely at-
tempted even though it is likely a better model to mimic real-
world human-to-human transmission events. Although the 
circulating Abs elicited by the regimen described in this paper 
neutralized SHIV-SF162P4 in vitro with reasonable potency, 
only a modest vaccine effect was observed upon in vivo rectal 
challenge. Upon closer examination, this outcome is perhaps 
not surprising. In the Barnett studies, an effective impact on 
acquisition was observed with homologous vaginal (Barnett   
et al., 2008) or rectal (Barnett et al., 2010) SHIV-SF162P4 chal-
lenge. The plasma neutralizing titers observed in the Barnett 
studies were generally higher against the homologous SHIV-
SF162P4 than those elicited by the heterologous YU2 trimers 
here. To mediate protection, some circulating IgG induced 
by systemic immunizations would be expected to enter the 
mucosa by transcytosis (Rojas and Apodaca, 2002), which is 
consistent with the detection of mAbs in mucosal washes after 
intravenous infusion of mAbs (Mascola et al., 2000; Parren   
et al., 2001; Hessell et al., 2009b). In our measurements, the 
Ab titers in the rectal mucosa were approximately four orders 
of magnitude lower than those in plasma, likely bringing the 
neutralization titers below effectiveness with regard to viral 
Evidence for short half-lives of Env-specific Abs was also   
presented in a recent study based on gp120-vaccinated and 
HIV-1–infected individuals (Bonsignori et al., 2009).
Although the frequency of Env-specific memory B cells in 
PBMCs was high at the time points measured in our study, 
we were unable to detect total IgG+ or Env-specific memory 
B cells in the bone marrow. This is consistent with a recent 
study reporting a lack of detectable memory B cells in the   
human bone marrow. Instead, the spleen was shown to be the 
major reservoir for human memory B cells (Mamani-Matsuda 
et al., 2008). In this regard, we note that many basic aspects of 
rhesus macaque B cell biology remain uncharacterized despite 
their frequent use as a nonhuman model. We suggest that the 
systems of analysis described in the current study, including 
the protocols for in vitro expansion and differentiation of 
memory B cells, have broad applications for studies aimed at 
understanding the distribution and frequency of functionally 
distinct B cell subsets in NHPs and to assess them relative to 
human biology and vaccine-elicited immune responses.
High titers of circulating Abs capable of neutralizing a panel 
of sensitive viruses spanning clades A, B, and C were shown 
here,  but  improvements  in  Env  immunogen  design  and/or 
mode of administration are needed to achieve neutralization of 
primary viruses represented in the Tier 2 panel used here. The 
relatively short immunization schedule used here and in many 
other preclinical immunogenicity studies may not allow opti-
mal maturation of the B cell response. With the intervals of 
antigen exposure used in this study, we observed no improve-
ment in the breadth of neutralization with boosting despite an 
increase in neutralizing activity against sensitive Tier 1 viruses. 
Early HIV-1 Env studies in baboons suggest that longer in-
tervals between immunizations may provide some benefit   
(Anderson et al., 1989). Further analyses are needed to address 
this question in a comprehensive and systematic manner.
In light of the renewed interest in the responses elicited 
by the monomeric gp120 proteins used in the VAX04 and 
RV144 phase III clinical trials, we sought to directly compare 
the neutralizing Ab activity elicited by the monomeric gp120 
used in VAX04 with that elicited by the trimers in NHPs. 
Previous evaluation of the antigenic properties of the YU2 
trimers show that they possess several of the features desired 
of an immunogen aimed to elicit bNAbs, such as occlusion of 
nonneutralizing epitopes in the C- and N-terminal domains 
of gp120 and recognition by a set of broadly neutralizing 
mAbs (Yang et al., 2000). Consistent with this, the YU2 tri-
mers are superior to monomeric YU2 gp120 for elicitation of 
neutralizing Abs in small animals (Li et al., 2006). However, 
a direct comparison between the VAX04 monomeric gp120 
immunogen and the YU2 trimeric immunogens was not pre-
viously performed. In our in vitro neutralization comparison, 
we observed a broader response in the trimer-inoculated ma-
caques than in the monomer-inoculated humans. Although 
there are several caveats to this comparison, this analysis pro-
vides initial benchmark information about the gp140 trimer-
elicited response in NHPs relative to the response elicited by 
monomeric gp120 in humans.JEM VOL. 207, August 30, 2010 
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an Avitag sequence inserted at the C terminus of each Env probe, allowing 
for covalent linkage of biotin to the lysine residue in the motif distal to the 
Env antigenic surface.
Animals. 12 rhesus macaques (Macaca Mulatta) of Chinese origin, 3 yr 
old, and four cynomolgus macaques of Chinese origin, 5 yr old, were 
housed at the animal facility Astrid Fagraeus Laboratory at the Swedish Insti-
tute for Infectious Disease Control. Housing and care procedures were in 
compliance with the provisions and general guidelines of the Swedish Board 
of Agriculture, and the facility has been assigned an Animal Welfare Assur-
ance number by the Office of Laboratory Animal Welfare (OLAW) at   
National Institutes of Health. All procedures were approved by the Local 
Ethical Committee on Animal Experiments (Stockholms Norra Djurförsök-
setiska Nämnd). The animals were housed in pairs in 4-m3 cages, enriched 
to give them possibility to express their physiological and behavioral needs. 
They were habituated to the housing conditions for >6 wk before the start 
of the experiment and subjected to positive reinforcement training to reduce 
the stress associated with experimental procedures. All immunizations and 
blood samplings were performed under sedation with 10 mg/kg ketamine 
i.m. (100 mg/ml Ketaminol; Intervet), and when sampled for rectal or vagi-
nal lavages or bone marrow the macaques were given an additional 0.5 mg/kg 
i.m. Xylazine (Rompun; Bayer) to induce total muscle relaxation and anal-
gesia. The macaques were weighed at each immunization or sampling occa-
sion. Before entering the study, all animals were confirmed negative for SIV, 
simian T cell lymphotropic virus, and simian retrovirus type D.
Immunizations and sampling. The 12 rhesus macaques (two groups of 
six animals) were inoculated five times with the immunogens described in 
the Expression and purification of Env immunogens section. Immuniza-
tions were performed at weeks 0, 4, 8, 12, and 18 by the i.m. route of   
injection. All protein immunizations were administered in 75 µg ABISCO-
100 (Isconova AB) and 500 µg CpG ODN2395 (Coley Pharmaceutical 
Group) as adjuvant (Abisco-100 + CpG). Protein doses were 200 µg per 
animal for the first inoculation and 100 µg for the subsequent injections. 
The vaccine was given in a total volume of 1 ml, divided equally between 
the left and right hind leg. Blood and rectal lavage samples were taken be-
fore and 1 and 2 wk after each immunization. The rectal mucosa was sam-
pled through insertion of a syringe and rinsing with 4 ml PBS. The lavage 
was then added to a concentrated cocktail of protease inhibitors, spun, and 
the liquid phase frozen at 80°C. Vaginal lavage was taken 2 wk after each 
immunization through insertion of a pediatric feeding tube and rinsing 
with 2 ml PBS. The vaginal lavage was then treated as for rectal samples.   
3 wk after immunizations two and four, the macaques were sampled for 
bone marrow through strictly aseptic insertion of a pediatric spinal needle 
between the greater and lesser tuberosity of humerus. A maximum of 5 ml 
was aspirated from each animal into a heparinized syringe and transferred 
to an EDTA tube.
PBMC isolation and in vitro stimulation. Bleeds were taken in EDTA-
coated tubes and spun at 1,200 g for 15 min for separation of plasma. The 
mononuclear  cells  were  purified  through  density  gradient  centrifugation 
with Ficoll-Paque (GE Healthcare) according to the manufacturer’s instruc-
tions and then counted and frozen in 90% heat-inactivated FBS and 10% 
DMSO (Sigma-Aldrich). Experiments were performed on both frozen and 
fresh cells. PBMCs were thawed in a 37°C water bath followed by two 
washes in RPMI 1640 media supplemented with 10% FBS, 2 mM L-Glutamine, 
100 U/ml penicillin, 100 µM streptomycin, 2% Hepes (all from Sigma- 
Aldrich), and 50 mM 2-ME (Invitrogen) before resting at 37°C supple-
mented with 5% CO2 overnight (ON). The PBMCs were cultured at 2 × 106 
cells/ml in a total of 500 µl per well in 48-well flat bottom plates (Thermo 
Fisher Scientific). The stimulation mix was composed of different combina-
tions of 5 µg/ml CpG ODN 10103 (TCGTCGTTTCGTCGTTTTGTC-
GTT; Coley Pharmaceuticals), PWM (Sigma-Aldrich), SAC strain 1/10,000 
(Sigma-Aldrich), 100 ng/ml interleukin 2, 100 ng/ml interleukin 10, and   
1 µg/ml of soluble CD40 ligand (Peprotech).
challenge via this route of exposure. Further improvements   
in the specificity and affinity of vaccine-elicited neutralizing 
Abs may be needed for this process to be efficient enough to 
achieve protection against heterologous rectal challenge. For 
an antibody-dependent HIV-1 vaccine, the rectal route of 
challenge may be more difficult to protect against because of 
lower levels of exudates and more readily available CD4+/
CCR5+ gut-associated target cells. Regimens designed to stimu-
late mucosal immune responses, including the production of 
antigen-specific secretory IgA, may provide benefit (Kozlowski 
and Neutra, 2003; Sundling et al., 2008), even though muco-
sal immunization was not required for protection against ho-
mologous infection via the vaginal route in a previous study 
(Barnett et al., 2008).
In conclusion, the extreme genetic diversity of circulating 
HIV-1 variants worldwide remains the main challenge for the 
development of an effective HIV-1 vaccine. Because of the 
difficulties in eliciting bNAbs through vaccination, the field 
has been spurred to dissect B cell responses in chronically in-
fected individuals who display such activities. In parallel with 
these efforts, we contend that it is important to characterize   
B cell responses elicited by Env vaccination in healthy primates 
where potential pathogenic effects caused by chronic HIV-1 
infection are not operational. In this regard, macaques offer 
several advantages as a result of their close genetic relationship 
with humans, their susceptibility to infection with SIV/SHIV, 
and because a more limited number of vaccine candidates can 
be tested in human clinical trials compared with in NHPs. 
The data presented here provide substantial insight into many 
issues relative to Env-specific primate B cell responses. Addi-
tional well designed HIV-1 vaccine and SHIV challenge 
studies, in coordination with selected human immunogenicity 
studies, are likely required to fully dissect the protective re-
quirements at relevant portals of viral entry.
MATERIALS AND METHODS
Expression and purification of Env immunogens. Soluble gp140 tri-
mers (gp140-F) were produced by transient transfection of Freestyle 293F 
suspension cells (Invitrogen) as previously described (Forsell et al., 2008). 
In brief, cells were transfected at a density of 1 × 106/ml in GIBCO Free-
style293 expression media using 293Fectin, according to manufacturer’s 
instructions (Invitrogen). Supernatants were collected 4 d after transfec-
tion.  After  collection,  all  supernatants  were  centrifuged  at  3,500  g  to   
remove cells or cell debris, filtered through a 0.22-µm filter, supplemented 
with Complete EDTA-free protease inhibitor cocktail (Roche) and penicillin-
streptomycin (Invitrogen), and stored at 4°C until further purification. 
First,  the  proteins  were  captured  via  glycans  by  lentil-lectin  affinity   
chromatography (GE Healthcare). After extensive washing with PBS, 
supplemented with 0.5 M NaCl, the proteins were eluted with 1 M 
methyl--d-mannopyranoside  and  captured  in  the  second  step  via  the 
His-tag  by  nickel-chelation  chromatography  (GE  Healthcare).  After  a 
wash with 40 mM imidazole (IM) and 0.5M NaCl in PBS, proteins were 
eluted with 300 mM IM in PBS. Trimers were then separated from lower 
molecular weight forms by gel filtration chromatography using a super-
dex200 26/60 prep grade column by the ÄKTA Fast protein liquid chro-
matography system (GE Healthcare). Biotinylated Env probes used in the 
B cell ELISPOT assay were purified by lentil-lectin and nickel-chelation 
chromatography but not subjected to subsequent gel filtration chromatog-
raphy. The biotinylation was performed using site-specific biotinylation of 2014 B cell responses against Env trimers in primates | Sundling et al.
suggesting that Abs recognizing both linear and conformational epitopes are 
detected under the assay conditions used in the present study.
B cell ELISpot assay. The frequency of antigen-specific memory B cells was 
determined as previously described (Douagi et al., 2010). In brief, total PBMCs 
were cultured at 2 × 106 cells/ml and stimulated with 5 µg/ml CpG-B (ODN-
10103; Coley), 10 µg/ml PWM (Sigma-Aldrich), and SAC (1:10,000; Sigma-
Aldrich) for 4 d in 48-well plates. To detect Ab-secreting cells, MAIPSWU10 
96-well plates (Millipore) were coated with 10 µg/ml of anti–human IgG 
(Fc; Jackson ImmunoResearch Laboratories) and PBMCs were transferred to 
the plates in dilution series and incubated ON at 37°C in 5% CO2. The plates 
were then washed with PBS containing 0.05% Tween and incubated with bi-
otinylated gp140-F, gp120-F, or gp120V1/2/3-F (Dosenovic et al., 2009) 
followed by washing and incubation with streptavidin-AP (Mabtech). The   
reactions were developed using BCIP/NBT substrate (Sigma-Aldrich) and 
stopped by washing in water. Spots corresponding to ASC were counted using 
an Immunospot analyzer (Cellular Technology Ltd.). The results were con-
verted to Ab-secreting cells per million cultured PBMCs (ASCs/106 PBMCs 
cells). Percentages of gp41 and variable region 1/2/3-specific memory B cells 
were calculated using the formulas (gp140-gp120)/gp140 × 100 and (gp120-
gp120V1/2/3)/gp140 × 100, respectively.
Virus neutralization assays. Plasmas from immunized animals were tested 
for virus neutralization capacity against a panel of diverse HIV-1 isolates. Neu-
tralization assays were performed using a single round of infection HIV-1   
Env pseudovirus assay and TZM-bl target cells as previously described   
(Li et al., 2005; Shu et al., 2007). Env pseudoviruses were prepared by co-
transfecting 293T cells with an Env expression plasmid containing a full 
gp160 env gene and an env-deficient HIV-1 backbone vector (pSG3Env). 
To determine the serum dilution that resulted in a 50% reduction in RLU, 
serial dilutions of sera were performed and the neutralization dose–response 
curves were fit by nonlinear regression using a four-parameter hill slope 
equation programmed into JMP statistical software (JMP 5.1; SAS Institute 
Inc.). The results are reported as the serum neutralization ID50, which is the 
reciprocal of the serum dilution producing 50% virus neutralization. Diverse 
HIV-1 virus isolates, including viruses from clades A, B, and C, were used in 
the neutralization assays. Clade B viruses included a panel of Env pseudovi-
ruses that were recently characterized and recommended for use in assessing 
neutralization by HIV-1 immune sera (Li et al., 2005). Several investigators 
also provided replication-competent viruses or functional Env plasmids for 
pseudoviruses. D. Gabuzda (Dana Farber Cancer Institute, Boston, MA) 
provided the Env plasmids for YU2 and MuLV. Env plasmids for SF162 and 
JRFL were provided by L. Stamatatos (Seattle Biomedical Research Insti-
tute, Seattle, WA) and J. Binley (Torrey Pines Institute, La Jolla, CA), re-
spectively. The clade A DJ263.8 sequence was cloned from the original 
PBMC-derived virus (provided by F. McCutchan and V. Polonis, U.S. Mil-
itary HIV Research Program, Rockville, MD) and the clade C MW965 Env 
plasmid was obtained from the AIDS Research and Reagent Repository. 
Isolation of the Env plasmids BaL.01 were recently described by our labora-
tory (Shu et al., 2007) and the SS1196.1 Env was previously described   
(Li et al., 2005). Neutralization was also measured against the SHI-SF162P4 
stock and against a cloned Env from this stock, Env clone 41.1.
Human serum samples. 20 randomly chosen serum samples were ob-
tained  via  a  Materials  Transfer  Agreement  with  the  Global  Solutions  for   
Infectious Diseases. These sera were derived from volunteers from the Vax-
Gen Inc phase III clinical trial. At the time of sampling (month 12.5), the par-
ticipants had received four injections (months 0, 1, 6, and 12) of the AIDSVAX 
B/B vaccine containing 300 µg each of recombinant HIV-1MN– and   
HIV-1GNE8–derived gp120 in Alum adjuvant (Pitisuttithum et al., 2006).
SHIV  challenge. Plasma from an acutely SHIV-SF162P4 (Kraft et al., 
2007)–infected rhesus macaque was originally provided by L. Stamatatos and 
was first inoculated i.v. into a naive rhesus macaque. During peak vire-
mia, blood and bone marrow from this animal was injected into a second 
To evaluate the stimulatory effect on B cell and T cell proliferation 
through FACS analysis, PBMCs were first labeled with 0.5 µM CFSE for   
7 min at 37°C and then washed with complete media. The cells were then 
incubated with the indicated stimulation for 6 d, after which the cells were 
stained with Abs for CD20 (clone 2H7), CD4 (clone L200), CD8 (clone 
SK1), and CD27 (clone M-T271). All Abs (BD) were previously titrated for 
optimal staining using rhesus macaque PBMCs. Samples were collected on a 
FACSCalibur (BD) and analyzed using FlowJo software (Tree Star, Inc.). 
For experiments using sorted macaque cells, PBMCs were incubated with 
CD20- or CD4-conjugated magnetic beads (Miltenyi Biotec) and positive 
fractions were isolated using autoMACS (Miltenyi Biotec) separation ac-
cording to the manufacturer’s instructions. The purity of sorted cells was 
evaluated through FACS analysis and was >90% for the CD20+ fraction and 
between 50 and 90% for the CD4+ fraction. Contaminating cells in the 
CD4+ fraction were mainly CD20+ B cells. Human B cells were sorted by 
either CD20 or CD19 positive selection with magnetic beads as described 
according to the manufacturer’s instructions and were >90% CD20+ B cells. 
Human CD4+ T cells were sorted from buffy coats by negative selection   
using CD4+ T cell enrichment cocktail (STEMCELL Technologies Inc.) 
and were >95% CD3+ and CD4+, as determined by flow cytometry.
Analysis  of  Env-binding  Abs. HIV-1 gp120-specific plasma, rectal or 
vaginal IgG, and IgA was measured by ELISA as previously described (Mörner 
et al., 2009) with modifications. In brief, insect cell–produced YU2 gp120 
protein was coated onto MaxiSorp (Thermo Fisher Scientific) microtiter 
plates at 100 ng/well in 50 mM carbonate buffer, pH 9.6, ON at 4°C. After 
blocking in PBS containing 2% nonfat dry milk, samples were added and in-
cubated for 1.5 h at 37°C. The gp120-specific IgG or IgA was detected by 
adding secondary HRP-conjugated anti–monkey IgG (Nordic Immunology) 
or  anti–monkey  IgA  (KPL).  The  signal  was  developed  by  addition  of   
O-phenylenediamine (OPD; Sigma-Aldrich) or TMB+ (Invitrogen). Reactions 
were terminated by adding 1 M HCl and the OD was read at 492 (for OPD) 
or 450 (for TMB+) and 620 nm. Between each incubation step, the plates 
were washed six times with PBS 0.05% Tween 20. The half-max binding   
titers (OD50) for each sample was calculated by interpolation from mean 
OD50 values calculated from an immunized control plasma using the formula 
([(ODmax-ODmin)/2] + ODmin). As a result of dilution of the vaginal and 
rectal lavages upon sample collection, data were set in relation to the total 
amount of IgG or IgA in the sample. Total IgG and IgA was measured by 
coating plates with 200 ng/well of goat anti–human IgG (Jackson Immuno-
Research Laboratories) or 100 ng/well of goat anti–monkey IgA (KPL).
When ELISA was used to measure Env region-specific Abs, the plates were 
coated with the same molar ratios of gp140-F, gp120-F, or gp120V1/2/3-F   
as in the previous paragraph. Percentages of gp41 and variable region 1/2/3–
specific Abs were calculated using the formulas (gp140-gp120)/gp140 × 100 
and (gp120-gp120V1/2/3)/gp140 × 100. To calculate absolute concentra-
tions of gp120-specific Abs in samples, a gp140-F–immunized rhesus control sera 
was quantified for IgG gp120-specific Abs via a rhesus IgG standard (Southern-
Biotech) and subsequently used as standard for unknowns.
Avidity index was evaluated as described previously (Vermont et al., 2002; 
Lai et al., 2007) with some modifications. ELISA plates were coated overnight 
at 4°C with 100 ng/well Galanthus nivalis lectin (Sigma-Aldrich) in PBS. S2-
produced gp120 or 293F-produced gp140-F, gp120-F, or gp1201/2/3-F 
was added to the wells and incubated for 2 h at 37°C. Plasma was added in dilu-
tion series and incubated for 1.5 h before exposure to 1.5 M NaSCN or PBS 
for 10 min. The bound Abs were detected as in the ELISA described in the 
previous paragraph. Titers for each sample were calculated from the OD50 
value of an in-house standard plasma sample. The avidity index was calculated 
by dividing the titer for NaSCN-treated and PBS-treated samples and multi-
plying by 100. To determine if treatment with 1.5 M NaSCN disrupted the 
integrity of Env, we performed a dose titration experiment with increasing 
concentrations of NaSCN and assessed binding by a panel of mAbs directed 
against distinct gp120 epitopes (Fig. S4). The results demonstrate that recogni-
tion by several conformation-sensitive Abs (17b, b6, and F91) but not all   
(E51, 2.1C, b12, and F105) was retained after the 1.5-M NaSCN treatment, JEM VOL. 207, August 30, 2010 
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